Please login to the form below

Not currently logged in

New president at Bayer Healthcare

Dieter Weinand replaces departing Andreas Fibig
Bayer dieter Weinand

Bayer Healthcare has looked to Otsuka Pharmaceuticals to replace its departing president Andreas Fibig.

Dieter Weinand, who is currently president global commercialisation and portfolio management at Otsuka's US subsidiary, will step into his new role at Bayer Healthcare on August 1.

The announcement comes just one week after Weinand's predecessor Fibig announced his intention to leave Bayer Healthcare to join International Flavors & Fragrances as CEO.

Bayer Healthcare's parent group Bayer also announced this week that group CEO Marijn Dekkers will step down from his role at the end of 2016.

In addition to his time at Otsuka, Weinand boasts an impressive CV, serving across multiple regions and therapy areas for Pfizer and Bristole-Myers Squibb.

This includes roles as Pfizer's president for Asia-Pacific and as president for BMS' operations in Latin America and Canada.

6th June 2014

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?